Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NORTH CHICAGO, Ill., June 2, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced results of an analysis from the Phase 3 SELECT-PsA 2 clinical trial, showing that continuous treatment with RINVOQ® (upadacitinib, 15 mg, once daily) resulted in sustained improvements in disease activity for more than one year (56 weeks) among patients with active psoriatic arthritis who have responded inadequately to one or more biologic disease modifying anti-rheumatic drugs (bDMARDs).1 At week 56, 29 percent of patients treated with continuous RINVOQ 15 mg achieved minimal disease activitya (MDA).1 Results at week 56 were not multiplicity controlled.1 The full, long-term results from the Phase 3 SELECT-PsA 2 clinical trial will be presented at the EULAR 2021 Virtual Congress.

AbbVie to Present Analysis Evaluating Continuous RINVOQ® (upadacitinib) Treatment in Psoriatic Arthritis for More Than One Year at EULAR 2021 Virtual Congress

NORTH CHICAGO, Ill., June 2, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new analyses to be presented at the EULAR 2021 Virtual Congress showing patients with moderate to severe rheumatoid arthritis on background methotrexate (MTX) treated with RINVOQ® (upadacitinib, 15 mg, once daily) maintained higher rates of clinical remission and low disease activity through three years compared to those patients treated with HUMIRA® (adalimumab).1 Additionally, a separate integrated safety analysis found the safety profile of RINVOQ was consistent over 4.5 years, with no new safety risks observed.2 "We are dedicated to helping more people living with rheumatoid arthritis reach their treatment goals aimed at remission or low disease activity," said Mudra Kapoor, M.D.

New Long-Term Efficacy and Safety Analyses Evaluating RINVOQ® (upadacitinib) in Patients with Rheumatoid Arthritis to be Presented at EULAR 2021 Virtual Congress

Novavax

They might not reach the moon, but they won't fall into the gutter either.

Got $5,000? Buy These 2 Stocks Instead of Dogecoin

Jazz Pharmaceuticals

2 Biotech Cannabis Stocks To Watch Next Month As marijuana stocks continue… The post 2 Biotech Cannabis Stocks To Watch In June 2021 appeared first on Marijuana Stocks | Cannabis Investments and News. Roots of a Budding Industry.™.

2 Biotech Cannabis Stocks To Watch In June 2021

Algonquin Power & Utilities

British American Tobacco

Cardinal Health

Canadian Imperial Bank of Commerce

Canadian Natural Resources

Chevron

Enbridge

Novartis

Pembina Pipeline

Sanofi

AT&T

TC Energy

Kiplinger "insights for investors" online, first offered this list of 91 "Top Dividend Stocks From Around The World" July 13, 2020. Data updated 5/25/21 revealed 13 yields ripe for picking. These International “Dividend Aristocrats,” have raised dividends at least five straight years (Canadian) 10 years (European Union) or 25 years (U.S. companies).

The 91 'Best Dividend Stocks On Earth' For June

Kimberly-Clark

McDonald's

PepsiCo

We have covered the Dividend Aristocrat stocks for years here at 24/7 Wall St. So it was kind of a seismic shock when AT&T Inc.

5 High-Yielding Dividend Aristocrats May Be the Best Stocks to Own Now

Bristol-Myers

General Motors

Merck

Sirius XM Holdings Inc

Warren Buffett is a legendary investor, but he's wrong to pare down these top-tier stocks.

5 Stocks Warren Buffett Is Selling That You Should Be Buying

AbbVie Inc ( ABBV , Financial) has generally been associated with Humira since the company was spun off from Abbott Laboratories ( ABT , Financial) in early 2013. Humira has been one of the world's best-selling drugs over the past few years, but it is experiencing patent expirations in certain markets and will also see its U.S. patent expire very soon.

AbbVie: The Market Can't See Beyond Humira

European Commission grants approval to AbbVie (ABBV)/Roche's Venclyxto-based combinations for adults with newly diagnosed acute myeloid leukaemia

AbbVie's (ABBV) Venclyxto Gets EU Nod for First-Line AML

NORTH CHICAGO, Ill., May 26, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in Bernstein's 37th Annual Strategic Decisions Conference on Wednesday, June 2, 2021.

AbbVie to Present at Bernstein's 37th Annual Strategic Decisions Conference

NORTH CHICAGO, Ill., May 26, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced data from its migraine portfolio will be presented at the 2021 American Headache Society (AHS) Annual Scientific Meeting, to be held virtually June 3-6.

AbbVie to Present Data from its Leading Migraine Portfolio at the 2021 American Headache Society (AHS) Annual Scientific Meeting

AbbVie Inc. (ABBV) at 2021 UBS Global Healthcare Virtual Conference Call - (Transcript)

Roche Holding AG

The European Commission has approved AbbVie Inc's (NYSE: ABBV) Venclyxto (venetoclax) for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML). Venclyxto is approved in combination with a hypomethylating agent, azacitidine or decitabine, in AML patients ineligible for intensive chemotherapy.

AbbVie-Roche Win European Approval for Venclyxto in Newly Diagnosed Acute Myeloid Leukemia

NORTH CHICAGO, Ill., May 25, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that the European Commission (EC) has approved VENCLYXTO® (venetoclax) in combination with a hypomethylating agent, azacitidine or decitabine, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy.1 The approval is valid in all 27 member states of the EU, as well as Iceland, Liechtenstein, and Norway.

AbbVie Receives European Commission Approval of VENCLYXTO® (venetoclax) in Combination with a Hypomethylating Agent for Patients with Newly Diagnosed Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy

NORTH CHICAGO, Ill., May 25, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that it will present new data from a total of 41 abstracts covering its portfolio of immunology assets, including RINVOQ®, SKYRIZI®, HUMIRA® and its pipeline across multiple rheumatic diseases at the EULAR 2021 Virtual Congress of Rheumatology, to be held virtually June 2-5.

AbbVie Showcases the Depth of its Rheumatology Portfolio with New Data Presented at the EULAR 2021 Virtual Congress of Rheumatology

Owens & Minor

PerkinElmer

A tax refund is a great opportunity to invest in these three medical companies that have solid revenue growth ahead.

3 Strong Stocks for Your Income Tax Return

NORTH CHICAGO, Ill., May 24, 2021 /PRNewswire/ -- Late-breaking data analyses presented by AbbVie (NYSE: ABBV) at Digestive Disease Week® (DDW) Virtual Conference 2021 showed significantly greater proportions of patients with moderately to severely active Crohn's disease treated with both doses of investigational risankizumab (600 mg or 1200 mg) met the co-primary endpoints of clinical remission and endoscopic response at week 12 compared to placebo (p

AbbVie Presents New Late-Breaking Data Analyses Showing Risankizumab (SKYRIZI®) Achieves Clinical Remission and Endoscopic Response at Week 12 in Patients with Moderate to Severe Crohn's Disease

NORTH CHICAGO, Ill., May 24, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced The Lancet published primary analysis results from the pivotal global Phase 3 clinical trials – Measure Up 1, Measure Up 2 and AD Up – evaluating RINVOQ® (upadacitinib) in adults and adolescents with moderate to severe atopic dermatitis who were candidates for systemic treatment.

The Lancet Publishes Results from Pivotal Global Phase 3 Program Evaluating RINVOQ® (upadacitinib) in Atopic Dermatitis

Abbott Labs

Coca-Cola

Lowe's

You'll even have a little cash left over after buying these great dividend stocks.

The Best Dividend Aristocrats to Buy With $500 Right Now

Johnson & Johnson

UnitedHealth Group

Regular payouts can carry a lot of weight for a portfolio.

These Top 3 Healthcare Dividend Stocks Will Carry You Through Any Market Mood

Apple

These fundamentally strong stocks are well-positioned to weather tough market conditions.

3 Solid Stocks That Can Be Smart Picks Even in Choppy Markets

Enterprise Products Partners

Altria

MPLX

Vanguard Value ETF

Vanguard Growth ETF

5 Most Rewarding High-Yield Income Stocks With More Upside Potential

Amgen

Here's why you should consider buying into these two companies for the long run.

2 Healthcare Stocks Perfect to Buy Now and Hold Until Retirement

NORTH CHICAGO, Ill., May 20, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the UBS Global Healthcare Virtual Conference on Tuesday, May 25, 2021.

AbbVie to Present at the UBS Global Healthcare Virtual Conference

Aflac

iShares Morningstar Multi-Asset Income ETF

VanEck Morningstar Wide Moat ETF

SPDR Portfolio S&P 500 High Dividend ETF

Given the low interest rate environment, investors look for dividend shares. Here are seven long-term stocks for retirement portfolios.

News for AbbVie Stock (ABBV)